Dale Schaar

Rutgers, The State University of New Jersey

Also affiliated with Johnson University, Brunswick (United States), Rutgers Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome”.

A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-024-04742-9

N/A

0.533DataRank · unranked

16 citations

Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng, John Wright +5 more

A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol

eJHaem(2024)10.1002/jha2.991

N/A

0.297DataRank · unranked

5 citations

Ju‐Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H. Park +8 more

Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e19015

N/A

0DataRank · unranked

1 citations

Danielle Schafer, Dale Schaar, Roy Sabo, Dipankar Bandyopadhyay, Steven Grant +1 more